Sophie

Soluna Reveals Exciting December Progress: Significant Business Achievements and Project Developments

Retrieved on: 
Thursday, December 21, 2023
Data Management, Technology, Professional Services, Security, Telecommunications, Software, Artificial Intelligence, Cryptocurrency, Networks, Internet, Hardware, Sophie, Marketing, Annual report, PPA, ERCOT, Project, GAAP, Security (finance), Construction

The Company completed the marketing of the remaining slots at Sophie, with two finalist customers, one being a new addition to its customer roster.

Key Points: 
  • The Company completed the marketing of the remaining slots at Sophie, with two finalist customers, one being a new addition to its customer roster.
  • Site optimization from the recently added hosting customers is improving and preparation for deployment of a new hosting customer in January is underway.
  • Project Kati is expected to exit the ERCOT planning phase before the end of Q1 2024.
  • Statements that are not historical facts, including but not limited to statements about Soluna’s beliefs and expectations, are forward-looking statements.

SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation

Retrieved on: 
Wednesday, November 15, 2023
Sophie, Hypotension, Cannabinoid, Alzheimer's disease, Eating, IMCA, Delirium, FDA, Agitation, Dronabinol, Tolerability, MD, CMAI, Central nervous system, Pharmaceutical industry, Medical device, Hospital, Disease, Patient, Safety

Tel-Aviv, Nov. 15, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), unveiled positive topline results from its investigator-initiated Phase IIa trial at the Sophie & Abraham Stuchynski Israeli Alzheimer’s Medical Center (IMCA). The trial results indicated that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.

Key Points: 
  • The trial results indicated that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.
  • Agitation is a devastating symptom of Alzheimer's Disease (AD), afflicting nearly all patients as the disease progresses, and imposing tremendous suffering and caregiving burdens.
  • The results not only met primary endpoints regarding tolerability and adverse events but also demonstrated SCI-110's potential to alleviate agitation without side effects.
  • Moreover, when measured by the Cohen Mansfield Agitation Inventory (CMAI), our treatment led to a significant 23% reduction in agitation symptoms.

SKF appoints Sophie Arnius as Head of Investor Relations

Retrieved on: 
Thursday, August 31, 2023
Mergers and acquisitions, SKF, Mergers & Acquisitions, Sophie, Boliden, Electrolux

GOTHENBURG, Sweden, Aug. 31, 2023 /PRNewswire/ -- Sophie Arnius has been appointed Head of Investor Relations, starting latest 24 February 2024.

Key Points: 
  • GOTHENBURG, Sweden, Aug. 31, 2023 /PRNewswire/ -- Sophie Arnius has been appointed Head of Investor Relations, starting latest 24 February 2024.
  • Sophie joins SKF from Electrolux and she succeeds Patrik Stenberg who will continue in his role as Director, Mergers & Acquisitions.
  • Sophie Arnius has extensive experience from working towards the financial markets and with other relevant stakeholders.
  • She is currently Head of Investor Relations at Electrolux, and she has previously held similar positions at Boliden and BillerudKorsnäs.

SKF appoints Sophie Arnius as Head of Investor Relations

Retrieved on: 
Thursday, August 31, 2023
Mergers and acquisitions, SKF, Mergers & Acquisitions, Sophie, Boliden, Electrolux

GOTHENBURG, Sweden, Aug. 31, 2023 /PRNewswire/ -- Sophie Arnius has been appointed Head of Investor Relations, starting latest 24 February 2024.

Key Points: 
  • GOTHENBURG, Sweden, Aug. 31, 2023 /PRNewswire/ -- Sophie Arnius has been appointed Head of Investor Relations, starting latest 24 February 2024.
  • Sophie joins SKF from Electrolux and she succeeds Patrik Stenberg who will continue in his role as Director, Mergers & Acquisitions.
  • Sophie Arnius has extensive experience from working towards the financial markets and with other relevant stakeholders.
  • She is currently Head of Investor Relations at Electrolux, and she has previously held similar positions at Boliden and BillerudKorsnäs.

Sophie's BioNutrients Develops Chlorella Ice Cream with More Iron and B12 Than Cow's Milk

Retrieved on: 
Tuesday, June 27, 2023
DTI, Food technology, Ice cream, Microalgae, Transcendence (Devin Townsend Project album), Chlorella vulgaris, Carbon, Milk, European Food Safety Authority, Iron, EFSA, Vitamin B12, Entrepreneurship, Environment, Dairy, Dietary supplement, Chlorella, Sophie

Made with Sophie's dairy-free Chlorella Protein Concentrate, the new vegan ice cream boasts a complete nutritional panel, with more B12 and iron than most dairy and plant-based alternatives.

Key Points: 
  • Made with Sophie's dairy-free Chlorella Protein Concentrate, the new vegan ice cream boasts a complete nutritional panel, with more B12 and iron than most dairy and plant-based alternatives.
  • Sophie's Chlorella Protein is a neutral-hued microalgae flour naturally cultivated from Chlorella vulgaris.
  • The company states the Chlorella vulgaris strains it uses are US GRAS and European Food Safety Authority (EFSA) approved as food ingredients.
  • According to Sophie's, a 1 oz serving of chlorella ice cream has the potential to provide double the recommended daily intake of Vitamin B12.

Sophie's BioNutrients Develops Chlorella Ice Cream with More Iron and B12 Than Cow's Milk

Retrieved on: 
Tuesday, June 27, 2023
DTI, Food technology, Ice cream, Microalgae, Multimedia, Transcendence (Devin Townsend Project album), Chlorella vulgaris, Carbon, Milk, European Food Safety Authority, Iron, EFSA, Vitamin B12, Entrepreneurship, Environment, Dairy, Dietary supplement, Chlorella, Sophie

Made with Sophie's dairy-free Chlorella Protein Concentrate, the new vegan ice cream boasts a complete nutritional panel, with more B12 and iron than most dairy and plant-based alternatives.

Key Points: 
  • Made with Sophie's dairy-free Chlorella Protein Concentrate, the new vegan ice cream boasts a complete nutritional panel, with more B12 and iron than most dairy and plant-based alternatives.
  • Sophie's Chlorella Protein is a neutral-hued microalgae flour naturally cultivated from Chlorella vulgaris.
  • The company states the Chlorella vulgaris strains it uses are US GRAS and European Food Safety Authority (EFSA) approved as food ingredients.
  • According to Sophie's, a 1 oz serving of chlorella ice cream has the potential to provide double the recommended daily intake of Vitamin B12.

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Retrieved on: 
Friday, June 2, 2023
Edinburgh, CMAI, Central nervous system, Delirium, Alzheimer's disease, Benzodiazepine, Hypotension, Disease, Tolerability, Eating, Quality of life, IMCA, Falls, Appetite, Doctor of Philosophy, Agitation, Dementia, MD, Mini–Mental State Examination, SD, AD, SCI, Edinburgh Feeding Evaluation in Dementia Scale, Sophie, Pharmaceutical industry, Medical imaging, Safety, Patient

Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.

Key Points: 
  • Agitation manifests over the course of AD’s progression in almost all affected patients, increasing patients’ suffering and burden of care.
  • This Phase IIa clinical trial was an open label  trial, which included 18 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and efficacy trends of twice daily oral administration of SCI-110.
  • In general, the trial medication was well tolerated with no negative response to the treatment observed throughout the trial duration.
  • Alzheimer disease' patients experience many different symptoms that deteriorate their condition including lack of appetite, sleep quality and agitation.

Sophie's BioNutrients Debuts Chlorella Ice Cream to Storm the Vegan Ice Cream Industry

Retrieved on: 
Monday, November 7, 2022
Food technology, Northwestern Technological Institute, European Food Safety Authority, Awareness, MassChallenge, Institute, CAGR, COVID, Transcendence (Devin Townsend Project album), Food, Ice cream, Chlorella vulgaris, Iron, EFSA, Microalgae, Nature, CEO, Seafood, Research, Meat, US, COVID 19, Saudi Research and Marketing Group, Entrepreneurship, Environment, Goal, Technology, Carbon, DTI, Dietary supplement, Aquaculture, Chlorella, B12, Sophie

WAGENINGEN, Netherlands, Nov. 7, 2022 /PRNewswire/ -- Sophie's BioNutrients, a next-generation sustainable urban food production technology company, together with Danish Technological Institute (DTI), a green solutions facilitator in Denmark, collaborated to produce its first chlorella-based ice cream, made from Sophie's BioNutrients dairy-free Chlorella Protein Concentrate. With vegan, dairy-free options for ice cream on the rise in response to growing consumer demands for plant-based alternatives, this 100% plant-based ice cream is a much-anticipated addition.

Key Points: 
  • Sophie's BioNutrients introduces sustainable and nutritious ice cream with double the action for the sweet tooth.
  • With vegan, dairy-free options for ice cream on the rise in response to growing consumer demands for plant-based alternatives, this 100% plant-based ice cream is a much-anticipated addition.
  • Unlike conventional plant-based ice cream, this ice cream innovation boasts a complete nutrition profile, and in combination with other functional ingredients mimics natural ice cream texture and can be easily made into several popular ice cream flavors with add-on toppings.
  • A one ounce serving of chlorella ice cream has the potential to provide double the recommended daily intake of B12.

Sophie's BioNutrients Debuts Chlorella Ice Cream to Storm the Vegan Ice Cream Industry

Retrieved on: 
Monday, November 7, 2022
Food technology, Northwestern Technological Institute, European Food Safety Authority, Awareness, MassChallenge, Multimedia, Institute, CAGR, COVID, Transcendence (Devin Townsend Project album), Food, Ice cream, Chlorella vulgaris, Iron, EFSA, Microalgae, Nature, CEO, Seafood, Research, Meat, US, COVID 19, View, Saudi Research and Marketing Group, Entrepreneurship, Environment, Goal, Technology, Carbon, DTI, Dairy product, Dietary supplement, Aquaculture, Chlorella, B12, Sophie

WAGENINGEN, Netherlands, Nov. 7, 2022 /PRNewswire/ -- Sophie's BioNutrients, a next-generation sustainable urban food production technology company, together with Danish Technological Institute (DTI), a green solutions facilitator in Denmark, collaborated to produce its first chlorella-based ice cream, made from Sophie's BioNutrients dairy-free Chlorella Protein Concentrate. With vegan, dairy-free options for ice cream on the rise in response to growing consumer demands for plant-based alternatives, this 100% plant-based ice cream is a much-anticipated addition.

Key Points: 
  • Sophie's BioNutrients introduces sustainable and nutritious ice cream with double the action for the sweet tooth.
  • With vegan, dairy-free options for ice cream on the rise in response to growing consumer demands for plant-based alternatives, this 100% plant-based ice cream is a much-anticipated addition.
  • Unlike conventional plant-based ice cream, this ice cream innovation boasts a complete nutrition profile, and in combination with other functional ingredients mimics natural ice cream texture and can be easily made into several popular ice cream flavors with add-on toppings.
  • A one ounce serving of chlorella ice cream has the potential to provide double the recommended daily intake of B12.

Why Scaleups like Sophie's Bionutrients are Flocking to Food (not Silicon) Valley

Retrieved on: 
Tuesday, May 3, 2022
Silicon, Food industry, Agriculture, Pesticide, Water, Time, Eye, Seafood, Population growth, Program, Sophie, Food technology, Food, Meat, Fermentation, Microalgae, Protein, Earth Day, Growth, Nature, Aquaculture

WAGENINGEN, Netherlands, May 3, 2022 /PRNewswire/ -- Six months ago, micro-algae protein pioneer Sophie's Bionutrients decided to move its Singapore headquarters to the global alt-protein hotspot "Food Valley" in The Netherlands. Since then, the biotech scaleup found specialized production partners, has completed its C-level suite with Dutch talent, identified specialist support in various areas, is signing commercial agreements and and is on the verge of closing the next round of fund raising. What enabled this very speedy 'landing'?

Key Points: 
  • "The highly developed 'Food Valley' eco-system is similar to that of Silicon Valley, but focused on ag- and foodtech", says Eugene Wang, Founder and Co-CEO.
  • "As the hub of agrifoodtech innovation, Food Valley is the ideal springboard for Sophie's Bionutrients to take the next step in its journey to market.
  • Sophie's Bionutrients' six-month anniversary in Food Valley coincides with Earth Day, the global movement that encourages leaders to "Invest in our Planet".
  • Sophie's Bionutrients, a B2B food technology company, is on a mission to unleash the limitless possibilities of nature, restore our planet and eliminate food allergies.